The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
About one in eight adults say that they are currently taking a GLP-1 drug either to lose weight or treat a chronic condition, an increase from 18 months ago, though the high costs of the medications remain a concern. Few adults think it is likely their prescription costs will go down as a result of recently announced Trump administration policies.
About one in eight adults (12%) say that they are currently taking a GLP-1 drug such as Ozempic or Wegovy either to lose weight or treat a chronic condition, an increase from 18 months ago, though the high costs of the medications remain a concern, a new KFF Health Tracking Poll finds. Overall nearly one in five adults (18%) say at some point they have taken a GLP-1 drug, a class of medications used for…
Some insurers in the ACA’s small group market are citing tariffs, particularly those affecting prescriptions drugs, as a reason for higher-than-expected premium increases.
This analysis of preliminary rate filings from 318 insurers across all 50 states and DC finds that small businesses with Affordable Care Act (ACA)-compliant plans could face a median premium increase of 11% for 2026.
Affordable Care Act (ACA) Marketplace plans rarely cover GLP-1 drugs approved solely for obesity treatment, according to a an analysis of 2024 federal plan data. Wegovy, a drug that is approved for weight loss, is covered by just 1% of Marketplace prescription drug plans, compared to 82% of Marketplace prescription drug plans for Ozempic, which contains the same active ingredient as Wegovy (semaglutide) but is approved only for diabetes. This analysis examines publicly available formularies…
As the Trump administration promotes its new TrumpRx website and other efforts to lower prescription drug prices, a growing majority of the public worries about being able to afford prescription drugs, and large majorities across parties want the government to do more to regulate prices, a new KFF Health Tracking Poll finds.
Summary of Key Changes to Medicare in 2010 Health Reform Law . This brief provides a detailed look at the improvements in Medicare benefits, changes to payments for providers and Medicare Advantage plans, various demonstration projects and other Medicare provisions in the law. It includes a timeline of key dates for implementing the Medicare-related provisions in the law.
The brief examines current funding for comparative effectiveness research, the provisions included in the current health reform legislation, and issues related to which treatments that might be studied, whether and how to weigh costs of care, and how such findings will be used and shared with health-care practitioners and the public. It is part of the Foundation's series of Explaining Health Reform briefs on key concepts in health reform. Brief (.pdf)
State Financing of the Medicare Drug Benefit: New Data on the "Clawback" Beginning in 2006, states will be obligated to finance part of the new Medicare prescription drug benefit via a monthly "clawback" payment to the federal government. This issue update analyzes the latest data and provides an overview of the state financing of the Medicare drug benefit. Issue Brief (.pdf)
A new survey by NPR, the Kaiser Family Foundation, and Harvard s Kennedy School of Government finds that many Americans have real problems when it comes to accessing and paying for health care, and even if they haven't yet faced a problem, many worry about getting and paying for care in the future. The survey also shows that, while people think helping seniors with the cost of prescription drugs should be a priority, most seniors…
© 2026 KFF